Faisal Zain stands at the forefront of the medical technology landscape, bringing years of specialized experience in the manufacturing and implementation of advanced diagnostic tools. His career has been defined by a commitment to bridging the gap between raw data and actionable clinical insights, ensuring that the technology used in modern medicine serves both the provider and the patient with equal precision. With the recent news of Novellia securing an $18 million Series A funding round, Zain offers his expert perspective on why the shift toward patient-permissioned data is not just a trend, but a necessary evolution for the pharmaceutical and diagnostic industries. He digs into the complexities of data fragmentation and the human stories that drive innovation in this high-stakes field.
The pharmaceutical industry spends an astronomical amount on real-world data every year, yet there is a pervasive sense of frustration regarding the quality of those insights. Why do traditional data collection methods, which rely heavily on brokers and third-party intermediaries, fail to provide a cohesive narrative for researchers?
The reality is that pharmaceutical companies are often operating with one hand tied behind their backs, spending between $80 million and $100 million annually on data that is essentially a collection of disconnected snapshots. When you purchase information from brokers or large health systems, you are getting fragmented pieces of a puzzle that do not naturally fit together because the patient isn’t the one holding the pieces. These traditional vendors struggle to stitch together a single, complete story of a person’s healthcare journey, leaving researchers to guess what happened between different doctor visits or lab tests. Without direct patient consent and a centralized way to track every touchpoint, the industry remains stuck with data that lacks the longitudinal depth required for true scientific breakthroughs. It is incredibly difficult to assess the long-term safety or efficacy of a treatment when your data source is missing the quiet moments of a patient’s life outside of a specific hospital system.
Novellia recently attracted $18 million in new funding, led by Spark Capital and supported by names like Khosla Ventures and TMV, bringing their total to $28 million. From a technical standpoint, how does their patient-permissioned platform fundamentally change the way medical records are aggregated compared to the status quo?
This model represents a radical shift because it leverages emerging interoperability rules to put the patient in total control of their own medical history. Instead of a company hunting down records from various siloed databases, the platform allows individuals to aggregate years of records from every provider, lab, or clinic they have ever visited into one secure, unified profile. This creates a “patient-permissioned” ecosystem where the data flows directly from the source to the researcher with the user’s explicit blessing, ensuring the data is both ethically sourced and incredibly comprehensive. By bypassing the traditional intermediaries, they can offer pharma companies and diagnostic firms anonymized insights that are far more accurate than what could be bought on the open market. It’s a win-win scenario where the patient gets a free tool to manage their health journey while the scientific community gains access to a level of detail that was previously unreachable.
The inspiration for this platform was deeply personal for the founders, particularly regarding the challenges of navigating care for a family member with gastroesophageal cancer. How does this focus on the “human element” of data fragmentation improve the actual utility of the technology for the top pharma companies already using it?
When you build a platform based on the lived experience of watching a loved one struggle to coordinate care across multiple providers, you prioritize the gaps that a purely clinical mind might overlook. Shashi Shankar saw firsthand how fragmented healthcare data can be during his grandfather’s illness, and that emotional weight translates into a product that values the “longitudinal view” of a patient’s journey. This is why a majority of the top 10 pharma companies are already working with this platform; they recognize that a patient-centered approach captures the nuances of care variation. For example, the platform has already been used to study biomarker testing patterns, revealing significant differences in how physicians at centers of excellence practice compared to those in community settings. That kind of granular, human-centric insight is exactly what is missing from the cold, anonymized spreadsheets provided by traditional data brokers.
Precision is everything in medical research, yet you’ve noted that even professional lab records can contain significant errors. Can you elaborate on how a unified data platform can actually identify and correct these discrepancies to improve drug safety and research outcomes?
Data validation is one of the most underrated but critical benefits of moving toward a unified, patient-led record system. By comparing multiple data sources within a single patient’s profile, the platform can identify physician transcription errors in lab records that would have been completely missed in a fragmented dataset. We saw a powerful application of this when researchers analyzed safety signals for a specific breast cancer drug; the platform actually found a lower incidence of a suspected adverse event than what was previously believed, simply by having a clearer, more accurate picture of the patients’ histories. When researchers can trust that the data has been cross-referenced and validated against a complete medical narrative, they can make much more informed decisions about drug safety and efficacy. This level of integrity is what will eventually lead to more personalized treatments and faster regulatory approvals for life-saving medications.
What is your forecast for the real-world data industry?
I believe we are entering an era where the “data broker” model will become obsolete as patients realize the inherent value and power of their own medical information. Over the next five to ten years, I expect patient-permissioned platforms to become the primary gold standard for clinical evidence, forcing the entire industry to prioritize interoperability and radical transparency. Pharmaceutical companies will move away from spending $100 million on “maybe” and instead invest in direct-to-patient ecosystems that provide “definitely.” Ultimately, this shift will collapse the walls between different health systems, creating a truly global, unified database that works first for the individual and second for the researcher, leading to a much more efficient and compassionate healthcare system.
